We are live on
!
Find out more
BCM
BML Capital Management Portfolio holdings
AUM
$156M
1-Year Est. Return
129.82%
This Fund
S&P 500
This Quarter
Est. Return
+23.16%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$109M
AUM Growth
-$23M
(-17%)
Cap. Flow
-$12.8M
Cap. Flow
% of AUM
-11.73%
Top 10 Holdings %
Top 10 Hldgs %
93.88%
Holding
28
New
4
Increased
4
Reduced
5
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Instil Bio
TIL
|
+$2.81M |
| 2 |
Target
TGT
|
+$985K |
| 3 |
PMV Pharmaceuticals
PMVP
|
+$404K |
| 4 |
Arvinas
ARVN
|
+$379K |
| 5 |
KZR
Kezar Life Sciences
KZR
|
+$351K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
EPIX
ESSA Pharma
EPIX
|
+$7.18M |
| 2 |
Milestone Pharmaceuticals
MIST
|
+$2.2M |
| 3 |
ELEV
Elevation Oncology
ELEV
|
+$2.16M |
| 4 |
IMA
ImageneBio Inc
IMA
|
+$2.03M |
| 5 |
CNTB
Connect Biopharma Holdings
CNTB
|
+$981K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.71% |
| 2 | Technology | 0.99% |
| 3 | Consumer Staples | 0.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Aclaris Therapeutics
ACRS
$793M
| $27.1M | 24.79% |
14,250,000
| – | – |
|
2
Atea Pharmaceuticals
AVIR
$390M
| $21.7M | 19.85% |
7,473,963
-135,849
| -2% | -$464K |
|
|
ADVM
3
DELISTED
Adverum Biotechnologies
ADVM
| $13.9M | 12.68% |
3,057,526
| – | – |
|
|
4
Instil Bio
TIL
$50.3M
| $11.5M | 10.56% |
645,600
+110,701
| +21% | +$2.81M |
|
5
Oramed Pharmaceuticals
ORMP
$165M
| $8.36M | 7.66% |
3,167,231
+83,978
| +3% | +$186K |
|
|
6
PMV Pharmaceuticals
PMVP
$71.5M
| $7.41M | 6.78% |
5,292,000
+292,000
| +6% | +$404K |
|
|
ALMS
7
Alumis Inc
ALMS
$3.65B
| $4.83M | 4.42% |
1,210,415
| – | – |
|
|
LVTX
8
DELISTED
LAVA Therapeutics
LVTX
| $3.07M | 2.81% |
1,970,610
| – | – |
|
|
KZR
9
DELISTED
Kezar Life Sciences
KZR
| $2.81M | 2.57% |
720,787
+85,604
| +13% | +$351K |
|
|
CNTB
10
Connect Biopharma Holdings
CNTB
$150M
| $1.91M | 1.75% |
1,267,500
-554,058
| -30% | -$981K |
|
|
IMA
11
ImageneBio Inc
IMA
$60.7M
| $1.49M | 1.36% |
182,509
-153,333
| -46% | -$2.03M |
|
|
LONA
12
LeonaBio Inc
LONA
$67.8M
| $1.34M | 1.22% |
323,066
-1
| -0% | -$4 |
|
13
Astrotech Corp
ASTC
$15.5M
| $1.08M | 0.99% |
220,410
| – | – |
|
|
14
Target
TGT
$63.4B
| $897K | 0.82% |
+10,000
| New | +$985K |
|
15
VistaGen Therapeutics
VTGN
$9.4M
| $533K | 0.49% |
150,000
| – | – |
|
16
PUT
Walmart Inc
WMT
$909B
| $519K | 0.48% |
+265
| New | +$26.4K |
|
|
17
Arvinas
ARVN
$517M
| $426K | 0.39% |
+50,000
| New | +$379K |
|
18
Lisata Therapeutics
LSTA
$32.8M
| $288K | 0.26% |
109,841
-99,973
| -48% | -$251K |
|
|
MURA
19
DELISTED
Mural Oncology
MURA
| $119K | 0.11% |
+57,500
| New | +$124K |
|
20
Corvus Pharmaceuticals
CRVS
$1.25B
| – | – |
-118,766
| Closed | -$475K |
|
|
ELEV
21
DELISTED
Elevation Oncology
ELEV
| – | – |
-5,890,434
| Closed | -$2.16M |
|
|
EPIX
22
DELISTED
ESSA Pharma
EPIX
| – | – |
-4,221,546
| Closed | -$7.18M |
|
|
HLVX
23
DELISTED
HilleVax
HLVX
| – | – |
-91,913
| Closed | -$183K |
|
|
24
Milestone Pharmaceuticals
MIST
$148M
| – | – |
-1,136,091
| Closed | -$2.2M |
|
|
THRD
25
DELISTED
Third Harmonic Bio
THRD
| $0 | ﹤0.01% |
3,824,417
| – | – |
|
Similar funds
AIS
BWM
TI
CFG
IWA
PFO
HCWM
BCM
BML Capital Management's Q3 2025 Portfolio in Review
As of Q3 2025, BML Capital Management held 28 positions worth $109M, down 17% from $132M the previous quarter. Its ten largest holdings account for 94% of the portfolio.
BML Capital Management withdrew a net $12.8M in Q3 2025, closing 8 positions and reducing 5 holdings. Its most notable exit was ESSA Pharma, an estimated $7.18M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, BML Capital Management opened a new position in Target worth $897K.
- BML Capital Management's largest Q3 2025 buy was Target: 10,000 shares worth $897K.
- BML Capital Management added most to Instil Bio in Q3 2025, an estimated $2.81M increase.
- BML Capital Management's biggest Q3 2025 reduction was ImageneBio Inc, cutting an estimated $2.03M.
- BML Capital Management fully exited ESSA Pharma in Q3 2025, selling an estimated $7.18M.
- BML Capital Management's ten largest holdings make up 94% of its $109M portfolio in Q3 2025.
- BML Capital Management opened 4 new positions and closed 8 in Q3 2025.
- BML Capital Management's portfolio value fell 17% quarter-over-quarter to $109M.
Based on BML Capital Management's 13F filing for Q3 2025, filed 10 Nov 2025.